This is a working overview of thymalfasin, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-01-29 and is reviewed periodically as new material appears.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide, 28 residues | N-terminal fragment of prothymosin alpha |
| Molecular mass | About 3108 Da | Acetylated form |
| Isoelectric point | Near 4.2 | Acidic peptide |
| Appearance | White to off-white lyophilized powder | Common supplied form |
| Typical storage | -20 °C or below, dry | Solution stability is lower |
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
In this case, the objective is the creation of chassis genomes based on necessary genes and other required DNA sequences rather than the design of metabolic or regulatory pathways based on abstract criteria.
== Judicial process == Ba'athist Syria had a long history of arbitrary arrest, unfair trials and prolonged detention of suspects. Thousands of political prisoners remain in detention, with many belonging to the banned Muslim Brotherhood and the Communist Party. Since June 2000, more than 700 long-term political prisoners have been freed by President al-Assad, though an estimated 4,000 are reportedly still imprisoned. Information regarding those detained in relation to political or security-related charges is not divulged by the authorities. The government has not acknowledged responsibility for around 17,000 Lebanese citizens and Palestinians who "disappeared" in Lebanon in the 1980s and early 1990s and are thought to be imprisoned in Syria. In 2009, hundreds of people were arrested and imprisoned for political reasons. Military police were reported to have killed at least 17 detainees. Human rights activists are continually targeted and imprisoned by the government. On 18 September 2020, Netherlands demanded that the Syrian president Bashar al-Assad be held accountable for the war crimes and crimes against humanity committed during the civilian war. The Dutch officials sent a notice to the Syrian regime on the legal actions to be taken and submitted a case at the International Court of Justice on the Syrian government's failure to negotiate under the UN framework.
A laboratory information management system (LIMS), sometimes referred to as a laboratory information system (LIS) or laboratory management system (LMS), is a software-based solution with features that support a modern laboratory's operations. They tend to be handled by inventory laboratory technicians. Key features include—but are not limited to—workflow and data tracking support, flexible architecture, and data exchange interfaces, which fully "support its use in regulated environments". The features and uses of a LIMS have evolved over the years from simple sample tracking to an enterprise resource planning tool that manages multiple aspects of laboratory informatics. There is no useful definition of the term "LIMS" as it is used to encompass a number of different laboratory informatics components. The spread and depth of these components is highly dependent on the LIMS implementation itself. All LIMSs have a workflow component and some summary data management facilities but beyond that there are significant differences in functionality. Historically the LIMyS, LIS, and process development execution system (PDES) have all performed similar functions. The term "LIMS" has tended to refer to informatics systems targeted for environmental, research, or commercial analysis such as pharmaceutical or petrochemical work. "LIS" has tended to refer to laboratory informatics systems in the forensics and clinical markets, which often required special case management tools.
A, B, C, D, E, F, G, I, J, K, L, P, Q1, R, S, T, U, V, Z1, Z2 Qi, Jianzhao; Wu, Jing; Kang, Shijie; Gao, Jingming; Hirokazu, Kawagishi; Liu, Hongwei; Liu, Chengwei (August 2024). "The chemical structures, biosynthesis, and biological activities of secondary metabolites from the culinary-medicinal mushrooms of the genus Hericium: a review". Chinese Journal of Natural Medicines. 22 (8): 676–698. doi:10.1016/S1875-5364(24)60590-X. ISSN 1875-5364. Retrieved 2026-01-30. J, K Kawagishi, Hirokazu; Masui, Ayano; Tokuyama, Shinji; Nakamura, Tomoyuki (September 2006). "Erinacines J and K from the mycelia of Hericium erinaceum". Tetrahedron. 62 (36): 8463–8466. Bibcode:2006Tetra..62.8463K. doi:10.1016/j.tet.2006.06.091. ISSN 0040-4020. Retrieved 2026-01-30. Spangenberg, E. T.; Moneypenny, A.; Bozzo, G. G.; Perreault, M. L. (2025-06-23). "Unveiling the role of erinacines in the neuroprotective effects of Hericium erinaceus: a systematic review in preclinical models". Frontiers in Pharmacology. 16 1582081. doi:10.3389/fphar.2025.1582081. ISSN 1663-9812. PMC 12230622. L Wei, Jing; Li, Jia-yao; Feng, Xi-long; Zhang, Yilin; Hu, Xuansheng; Hui, Heping; Xue, Xiaodong; Qi, Jianzhao (2023-08-31). "Unprecedented Neoverrucosane and Cyathane Diterpenoids with Anti-Neuroinflammatory Activity from Cultures of the Culinary-Medicinal Mushroom Hericium erinaceus". Molecules. 28 (17): 6380. doi:10.3390/molecules28176380. ISSN 1420-3049. PMID 37687209. Z1, Z2 Rupcic, Zeljka; Rascher, Monique; Kanaki, Sae; Köster, Reinhard; Stadler, Marc; Wittstein, Kathrin (2018-03-06).
=== Analogues === In addition to deupsilocin, Helus Pharma has also patented other deuterated psilocin isotopologues. Other deuterated drugs related to deupsilocin include the deuterated dimethyltryptamine (DMT) isotopologues deudimethyltryptamine (HLP004; CYB004; DMT-d10; deudimethyltryptamine) and SPL028 (D2-DMT) and the deuterated phenethylamine HLP005 (CYB005).
Sources: en.wikipedia.org
== Description == Parkia biglobosa is a dicotyledonous angiosperm belonging to the family Fabaceae (Caesalpinioideae - Mimosoid clade). It is a deciduous perennial that grows to between 7 and 20 metres high, in some cases up to 30 metres. The tree is a fire-resistant heliophyte characterized by a thick dark gray-brown bark. The pods of the tree, commonly referred to as locust beans, are pink in the beginning and turn dark brown when fully mature. They are 30-40 centimetres long on average, with some reaching lengths of about 45 centimetres. Each pod can contain up to 30 seeds; the seeds are embedded in a sweet, powdery yellow pulp.
Ajahn Brahm agrees, writing that the main purpose of dependent origination is to explain "how there can be rebirth without a soul" and "why there is suffering, and where suffering comes to an end." Brahm cites the definitions of the nidanas in the Vibhaṅgasutta (SN 12.2) which clearly indicate that birth and death is meant literally. According to Brahm,Paṭicca-samuppāda shows the empty process, empty of a soul that is, which flows within a life and overflows into another life. It also shows the forces at work in the process, which drive it this way and that, even exercising sway in a subsequent life. Dependent origination also reveals the answer to how kamma done in a previous life can affect a person in this life. Brahm argues that there are two parallel processes at work in dependent origination (which are really one process looked at from different angles), one is delusion and kamma leading to rebirth consciousness (nidanas # 1 – 3) and the other is craving and clinging leading to existence and rebirth (# 8 – 11). Brahm describes this as follows: "deluded kamma and craving produce the fuel which generates existence and rebirth (into that existence), thereby giving rise to the start of the stream of consciousness that is at the heart of the new life." Furthermore, dependent origination explains rebirth without appeal to an unchanging self or soul (atman). Paul Williams sees dependent origination as closely connected with the doctrine of not-self (anatman) which rejects the idea there is an unchanging essence that moves across lives.
Cameron introduced the referendum in order to fulfill a manifesto pledge, but campaigned on the side of the "remain" vote, along with most of the other major parties. Some members of the Conservatives, as well as the Democratic Unionist Party (DUP) and UK Independence Party (UKIP), campaigned to "leave." The "leave" vote unexpectedly won, and a few hours later Cameron announced he would resign. A leadership election was held and Cameron was succeeded by Theresa May. May became the UK's second female prime minister after Margaret Thatcher, as well as the first woman to hold two of the Great Offices of State. She began the process of withdrawing the UK from the European Union, triggering Article 50 in March 2017. The following month, she announced a snap general election, with the aims of strengthening her hand in Brexit negotiations and campaigning on "strong and stable" leadership. This election resulted in a hung parliament, in which the Conservatives actually losing seats, despite the party winning its highest vote share since 1983. The loss of an overall majority prompted her to enter a confidence and supply arrangement with the DUP of Northern Ireland to support a minority government. After versions of her draft withdrawal agreement were rejected by Parliament three times, she resigned in 2019 and was succeeded by Boris Johnson, her former Foreign Secretary. Following further defeats in Parliament, Johnson prorogued parliament, an act deemed illegal by the Supreme Court.
The bacterial outer membrane is found in gram-negative bacteria. Gram-negative bacteria form two lipid bilayers in their cell envelopes - an inner membrane (IM) that encapsulates the cytoplasm, and an outer membrane (OM) that encapsulates the periplasm. The composition of the outer membrane is distinct from that of the inner cytoplasmic cell membrane - among other things, the outer leaflet of the outer membrane of many gram-negative bacteria includes a complex lipopolysaccharide whose lipid portion acts as an endotoxin - and in some bacteria such as E. coli it is linked to the cell's peptidoglycan by Braun's lipoprotein. Porins can be found in this layer.
Sources: en.wikipedia.org
It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.
Thymosin alpha-1 is a single defined 28-residue peptide, while the broader family includes unrelated peptides such as thymosin beta-4. The shared name reflects historical isolation from thymus tissue rather than a common structure. Confusion between the two is common in older literature.
No single pathway fully accounts for its reported effects. Several studies describe interaction with innate immune receptors and downstream cytokine changes, but the complete picture is not settled. Open questions remain about which effects occur at physiological concentrations.
Thymosin fraction 5 is a mixture of many peptides obtained from thymus tissue, while thymosin alpha 1 is a single defined 28-residue molecule. The two names appear together in older literature because the purified peptide was first obtained from that mixture.